Francesco Perrone, M.D., Ph.D.
National Cancer Institute, Naples
13
13
2
N/A
0
9
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+5 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sandro Pignata, M.D., Ph.D.
National Cancer Institute, Naples
Shared therapeutic areas:
Worked with same sponsors:
Ciro Gallo, M.D., Ph.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Worked with same sponsors:
Gennaro Daniele, M.D., Ph.D.
National Cancer Institute, Naples
Shared therapeutic areas:
Worked with same sponsors:
Ciro Gallo, M.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Worked with same sponsors:
Massimo Di Maio, M.D.
National Cancer Institute, Naples
Shared therapeutic areas:
Worked with same sponsors:
Nicoletta Colombo, M.D.
European Institute of Oncology
Shared therapeutic areas:
Worked with same sponsors:
Irene Floriani, Ph.D.
Mario Negri Institute
Shared therapeutic areas:
Worked with same sponsors:
Alessandro Morabito, M.D.,
National Cancer Institute, Naples
Shared therapeutic areas:
Worked with same sponsors:
Roldano Fossati, M.D.
Mario Negri Institute
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer
Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer
Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
All 13 trials loaded